碳离子放疗治疗前列腺癌的多中心前瞻性研究汇总分析
日本碳离子放射肿瘤学研究组汇总3家机构2157例前列腺癌患者的前瞻性研究数据,分析碳离子放疗的疗效与安全性。低、中、高危组5年生化复发无生存率分别为92%、89%、92%,5年病因特异性生存率分别为100%、100%、99%。2级晚期泌尿生殖毒性和胃肠道毒性发生率分别为4.6%和0.4%,≥3级毒性为0%。
要点
- 低、中、高危组5年bRFS分别为92%、89%、92%
- 低、中、高危组5年CSS分别为100%、100%、99%
- 2级晚期GU/GI毒性分别为4.6%和0.4%,≥3级毒性为0%
核心结论
- 首次多中心数据分析提示碳离子放疗治疗前列腺癌总体结局良好。
研究设计与样本
- 多中心观察性研究(J-CROS1501PR),汇总日本3家碳离子放疗机构的前瞻性研究数据,共2157例患者。
主要发现
- 低、中、高危组患者分别为263例(12%)、679例(31%)、1215例(56%)。
- 低、中、高危组5年生化复发无生存率分别为92%、89%、92%。
- 低、中、高危组5年病因特异性生存率分别为100%、100%、99%。
- 2级晚期泌尿生殖毒性和胃肠道毒性发生率分别为4.6%和0.4%,≥3级毒性发生率为0%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: A multi-institutional observational study (J-CROS1501PR) has been carried out to analyze outcomes of carbon-ion radiotherapy (CIRT) for patients with prostate cancer. PATIENTS AND METHODS: Data of the patients enrolled in prospective studies of following 3 CIRT institutions were analyzed: National Institute of Radiological Sciences (NIRS; Chiba, Japan), Gunma University Heavy Ion Medical Center (GHMC; Gunma, Japan), and Ion Beam Therapy Center, SAGA HIMAT Foundation (HIMAT; Saga, Japan). Endpoints of the clinical trial are biochemical recurrence-free survival (bRFS), overall survival (OS), cause-specific survival (CSS), local control rate (LCR), and acute/late adverse effects. RESULTS: A total of 2157 patients' data were collected from NIRS (n=1432), GHMC (n=515), and HIMAT (n=210). The number of patients in low-risk, intermediate-risk, and high-risk groups was 263 (12%), 679 (31%), and 1215 (56%), respectively. The five-year bRFS in low-risk, intermediate-risk, and high-risk patients was 92%, 89%, and 92%, respectively. The five-year CSS in low-risk, intermediate-risk, and high-risk patients was 100%, 100%, and 99%, respectively. The incidence of grade 2 late GU/GI toxicities was 4.6% and 0.4%, respectively, and the incidence of ⩾G3 toxicities were 0%. CONCLUSIONS: Favorable overall outcomes of CIRT for prostate cancer were suggested by the analysis of the first multi-institutional data.
引用
- Nomiya T, Tsuji H, Kawamura H, et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016. PMID: 27836119. doi:10.1016/j.radonc.2016.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。